Year : 2015  |  Volume : 9  |  Issue : 1  |  Page : 71-81

The evolution of spinal/epidural neostigmine in clinical application: Thoughts after two decades

Department of Biomechanics, Medicine and Rehabilitation of Locomotor Members, Teaching Hospital, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil

Correspondence Address:
Prof. Gabriela Rocha Lauretti
Rua Maestro Joaquim Rangel, 644, CEP 14025-610 Ribeirão Preto, São Paulo
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1658-354X.146319

Rights and Permissions

Since the first clinical application of analgesia following spinal anticholinesterase by 1940's, several clinical double-blind studies have been conducted to date, where intrathecal doses of neostigmine in humans ranged from 750 to 1 μg, due to side-effects. Conversely, epidural neostigmine has been evaluated in proportionally higher doses and represents an alternative, but still deserves more investigation concerning both acute and chronic pain, as it seems devoid of important side-effects.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded361    
    Comments [Add]    
    Cited by others 7    

Recommend this journal